Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside

The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is relat...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2016-07, Vol.8 (8), p.889-906
Main Authors: Kuhn, Chantal, Weiner, Howard L
Format: Article
Language:English
Subjects:
Animal models
Antigens
Apoptosis
Arthritis
Autoimmune diseases
CD3 antigen
Clinical trials
Cytokines
Dendritic cells
Diabetes
Disease
Endocrinology
foralumab
Genetic engineering
immune tolerance
Immunoglobulins
Immunological tolerance
Immunotherapy
Intravenous administration
Lymphocytes
Monoclonal antibodies
monoclonal CD3 antibodies
Mucosa
otelixizumab
teplizumab
Transplants & implants
Tregs
Tumor necrosis factor-TNF
Type 1 diabetes
visilizumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c509t-468affbe68ac9e92535c8a61b0089552997da6fd96b516a717ee0bf4056ae1093
cites cdi_FETCH-LOGICAL-c509t-468affbe68ac9e92535c8a61b0089552997da6fd96b516a717ee0bf4056ae1093
container_end_page 906
container_issue 8
container_start_page 889
container_title Immunotherapy
container_volume 8
creator Kuhn, Chantal
Weiner, Howard L
description The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.
doi_str_mv 10.2217/imt-2016-0049
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808672495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2323407597</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-468affbe68ac9e92535c8a61b0089552997da6fd96b516a717ee0bf4056ae1093</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMouK4evRe8eIkmbT4ab8v6CQteVvAW0nTCZmmbNWkP_nuzrngQPM07wzMD8yB0SclNWVJ56_sRl4QKTAhTR2hGJSdYMlYf_-bq_RSdpbQlRDAp2Awt1huIZgfT6G1hhtHj5X1V9GEItguD6b5nTWg9pLvCxdAXDQx2U4whhzb5Fs7RiTNdgoufOkdvjw_r5TNevT69LBcrbDlRI2aiNs41kItVoEpecVsbQRtCasV5qZRsjXCtEg2nwkgqAUjjGOHCACWqmqPrw91dDB8TpFH3PlnoOjNAmJKmNamFLJniGb36g27DFPM3SZdVWTEiuZKZwgfKxpBSBKd30fcmfmpK9F6ozkL1XqjeC828OvBuGqcIyfpsAvSh66H11g_wz-4XlMV7FQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2323407597</pqid></control><display><type>article</type><title>Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside</title><source>PubMed Central</source><creator>Kuhn, Chantal ; Weiner, Howard L</creator><creatorcontrib>Kuhn, Chantal ; Weiner, Howard L</creatorcontrib><description>The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2016-0049</identifier><language>eng</language><publisher>London: Future Medicine Ltd</publisher><subject>Animal models ; Antigens ; Apoptosis ; Arthritis ; Autoimmune diseases ; CD3 antigen ; Clinical trials ; Cytokines ; Dendritic cells ; Diabetes ; Disease ; Endocrinology ; foralumab ; Genetic engineering ; immune tolerance ; Immunoglobulins ; Immunological tolerance ; Immunotherapy ; Intravenous administration ; Lymphocytes ; Monoclonal antibodies ; monoclonal CD3 antibodies ; Mucosa ; otelixizumab ; teplizumab ; Transplants &amp; implants ; Tregs ; Tumor necrosis factor-TNF ; Type 1 diabetes ; visilizumab</subject><ispartof>Immunotherapy, 2016-07, Vol.8 (8), p.889-906</ispartof><rights>Future Medicine Ltd</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-468affbe68ac9e92535c8a61b0089552997da6fd96b516a717ee0bf4056ae1093</citedby><cites>FETCH-LOGICAL-c509t-468affbe68ac9e92535c8a61b0089552997da6fd96b516a717ee0bf4056ae1093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,783,787,27936,27937</link.rule.ids></links><search><creatorcontrib>Kuhn, Chantal</creatorcontrib><creatorcontrib>Weiner, Howard L</creatorcontrib><title>Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside</title><title>Immunotherapy</title><description>The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.</description><subject>Animal models</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Arthritis</subject><subject>Autoimmune diseases</subject><subject>CD3 antigen</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Dendritic cells</subject><subject>Diabetes</subject><subject>Disease</subject><subject>Endocrinology</subject><subject>foralumab</subject><subject>Genetic engineering</subject><subject>immune tolerance</subject><subject>Immunoglobulins</subject><subject>Immunological tolerance</subject><subject>Immunotherapy</subject><subject>Intravenous administration</subject><subject>Lymphocytes</subject><subject>Monoclonal antibodies</subject><subject>monoclonal CD3 antibodies</subject><subject>Mucosa</subject><subject>otelixizumab</subject><subject>teplizumab</subject><subject>Transplants &amp; implants</subject><subject>Tregs</subject><subject>Tumor necrosis factor-TNF</subject><subject>Type 1 diabetes</subject><subject>visilizumab</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LxDAQhoMouK4evRe8eIkmbT4ab8v6CQteVvAW0nTCZmmbNWkP_nuzrngQPM07wzMD8yB0SclNWVJ56_sRl4QKTAhTR2hGJSdYMlYf_-bq_RSdpbQlRDAp2Awt1huIZgfT6G1hhtHj5X1V9GEItguD6b5nTWg9pLvCxdAXDQx2U4whhzb5Fs7RiTNdgoufOkdvjw_r5TNevT69LBcrbDlRI2aiNs41kItVoEpecVsbQRtCasV5qZRsjXCtEg2nwkgqAUjjGOHCACWqmqPrw91dDB8TpFH3PlnoOjNAmJKmNamFLJniGb36g27DFPM3SZdVWTEiuZKZwgfKxpBSBKd30fcmfmpK9F6ozkL1XqjeC828OvBuGqcIyfpsAvSh66H11g_wz-4XlMV7FQ</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Kuhn, Chantal</creator><creator>Weiner, Howard L</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160701</creationdate><title>Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside</title><author>Kuhn, Chantal ; Weiner, Howard L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-468affbe68ac9e92535c8a61b0089552997da6fd96b516a717ee0bf4056ae1093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animal models</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Arthritis</topic><topic>Autoimmune diseases</topic><topic>CD3 antigen</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Dendritic cells</topic><topic>Diabetes</topic><topic>Disease</topic><topic>Endocrinology</topic><topic>foralumab</topic><topic>Genetic engineering</topic><topic>immune tolerance</topic><topic>Immunoglobulins</topic><topic>Immunological tolerance</topic><topic>Immunotherapy</topic><topic>Intravenous administration</topic><topic>Lymphocytes</topic><topic>Monoclonal antibodies</topic><topic>monoclonal CD3 antibodies</topic><topic>Mucosa</topic><topic>otelixizumab</topic><topic>teplizumab</topic><topic>Transplants &amp; implants</topic><topic>Tregs</topic><topic>Tumor necrosis factor-TNF</topic><topic>Type 1 diabetes</topic><topic>visilizumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuhn, Chantal</creatorcontrib><creatorcontrib>Weiner, Howard L</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>UK &amp; Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuhn, Chantal</au><au>Weiner, Howard L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside</atitle><jtitle>Immunotherapy</jtitle><date>2016-07-01</date><risdate>2016</risdate><volume>8</volume><issue>8</issue><spage>889</spage><epage>906</epage><pages>889-906</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.</abstract><cop>London</cop><pub>Future Medicine Ltd</pub><doi>10.2217/imt-2016-0049</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1750-743X
ispartof Immunotherapy, 2016-07, Vol.8 (8), p.889-906
issn 1750-743X
1750-7448
language eng
recordid cdi_proquest_miscellaneous_1808672495
source PubMed Central
subjects Animal models
Antigens
Apoptosis
Arthritis
Autoimmune diseases
CD3 antigen
Clinical trials
Cytokines
Dendritic cells
Diabetes
Disease
Endocrinology
foralumab
Genetic engineering
immune tolerance
Immunoglobulins
Immunological tolerance
Immunotherapy
Intravenous administration
Lymphocytes
Monoclonal antibodies
monoclonal CD3 antibodies
Mucosa
otelixizumab
teplizumab
Transplants & implants
Tregs
Tumor necrosis factor-TNF
Type 1 diabetes
visilizumab
title Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-13T13%3A52%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20anti-CD3%20monoclonal%20antibodies:%20from%20bench%20to%20bedside&rft.jtitle=Immunotherapy&rft.au=Kuhn,%20Chantal&rft.date=2016-07-01&rft.volume=8&rft.issue=8&rft.spage=889&rft.epage=906&rft.pages=889-906&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2016-0049&rft_dat=%3Cproquest_cross%3E2323407597%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c509t-468affbe68ac9e92535c8a61b0089552997da6fd96b516a717ee0bf4056ae1093%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2323407597&rft_id=info:pmid/&rfr_iscdi=true